chr18-51078307-T-C
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_005359.6(SMAD4):c.1499T>C(p.Ile500Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I500M) has been classified as Pathogenic.
Frequency
Consequence
NM_005359.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMAD4 | NM_005359.6 | c.1499T>C | p.Ile500Thr | missense_variant | 12/12 | ENST00000342988.8 | NP_005350.1 | |
SMAD4 | NM_001407041.1 | c.1499T>C | p.Ile500Thr | missense_variant | 12/12 | NP_001393970.1 | ||
SMAD4 | NM_001407042.1 | c.1499T>C | p.Ile500Thr | missense_variant | 12/12 | NP_001393971.1 | ||
SMAD4 | NR_176265.1 | n.2150T>C | non_coding_transcript_exon_variant | 13/13 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMAD4 | ENST00000342988.8 | c.1499T>C | p.Ile500Thr | missense_variant | 12/12 | 5 | NM_005359.6 | ENSP00000341551 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Myhre syndrome Pathogenic:6Other:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2012 | - - |
Pathogenic, no assertion criteria provided | literature only | Unit U781; INSERM (Institut National de la Santé Et de la Recherche Médicale) | - | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | May 09, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Jul 13, 2022 | This SMAD4 variant (rs281875321) is absent from a large population dataset and has been reported in ClinVar. This missense change has been identified in multiple unrelated individuals with Myhre syndrome. Ile500 lies in the MAD homology 2 (MH2) domain, a region at the C-terminus of the protein, which is required for TGF-beta/BMP signal transduction. Experiments using cultured skin fibroblasts from a patient with the p.Ile500Thr substitution showed decreased levels of SMAD4 ubiquitination with increased levels of SMAD4 protein, enhanced levels of phosphorylated SMAD2/3 and SMAD1/5/8 proteins, and decreased mRNA levels of downstream TGF-beta and BMP target genes compared to controls. This variant was not detected in specimens provided by the patient's mother and father and is apparently de novo. We consider c.1499T>C to be pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | The variant has been previously reported as de novo in a similarly affected individual (PMID: 22243968, PS2_S). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000030149, PMID:2215 8539, PS1_S). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.776, PP3_P). It is not observed in the gnomAD v2.1.1 dataset (PM2_M). The variant is located in a well-established functional domain or exonic hotspot, where pathogenic variants have frequently reported (PM1_M). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000030150, PMID:22158539,22158539, PM5_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | research | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jun 26, 2017 | Previously reported pathogenic variant, de novo in this case with maternity and paternity confirmed (PS2). - |
not provided Pathogenic:2Other:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 03, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies demonstrate a damaging effect: significantly increased transcription activity compared to wild type (PMID: 31654632); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22158539, 22585601, 27562837, 22243968, 27302097, 24424121, 24398790, 22683461, 24580733, 24715504, 11977156, 25252769, 30921096, 32917212, 35907855, 33057194, 35982159, 31654632, 17873119, 18823382, 15235019) - |
not provided, no classification provided | literature only | UniProtKB/Swiss-Prot | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | - | - - |
Juvenile polyposis syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 25, 2021 | Experimental studies have shown that this variant affects SMAD4 protein function (PMID: 31654632, 22158539). This variant has been observed in individual(s) with Myhre syndrome (PMID: 22158539, 27302097, 30921096, 24424121, 22243968). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 30149). This variant is not present in population databases (ExAC no frequency). This sequence change replaces isoleucine with threonine at codon 500 of the SMAD4 protein (p.Ile500Thr). The isoleucine residue is highly conserved and there is a moderate physicochemical difference between isoleucine and threonine. This variant disrupts the p.Ile500 amino acid residue in SMAD4. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22158539, 22243968, 22585601, 24398790, 26636501, 27302097, 24398790). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at